Whilst 85% of primary cancers (TCGA-PRAD) have matching PTEN and MIR346 copy number status, 102/150 (68%) of mCRPC show MIR346 and PTEN on different segments (Fig. 6A, Fig. S13A), suggestive of emergence of breakpoints between the two genes during disease progression. Here, PTEN is linked to prostate adenocarcinoma.